Inclusion is Our Goal
This basket study accepts patients with many different cancer types.
Basket trials like STARTRK-2 are designed to capture as many eligible patients as possible.
Entrectinib was developed to have an effect on tumors of any type with a chromosomal rearrangement affecting the NTRK1, NTRK2, NTRK3, ROS1, or ALK genes. Our research has identified disease states that most often harbor these mutations.
Ongoing research is still identifying additional tumor types initiated by NTRK-family, ROS1, or ALK gene fusion events.
STARTRK-2 is actually intended as a potentially registration-enabling study. This may be the first time a basket study will serve as a registration-enabling study. This is very exciting; we're transitioning from histological to molecular-based classification for therapy selection." Dr. Tony Mok, M.D., Chinese University of Hong Kong.
STARTRK-2 is also intended as a potentially registration-enabling study for the Trailblaze Pharos™ molecular diagnostic test.
Our two-step diagnostic assay identifies NTRK1, NTRK2, NTRK3, ROS1, and ALK oncogenic gene rearrangements in tumor tissue.
Explore the most prevalent NTRK1, NTRK2, NTRK3, ROS1, or ALK driven disease states
Read more about the tumor types found to carry NTRK1, NTRK2, NTRK3, ROS1, or ALK gene rearrangements.